EANS-Adhoc: Sartorius AG
Preliminary Figures for the First Nine Months of 2011
20.10.2011 – 20:59
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 20.10.2011 Group sales revenue rises 12.2% to EUR541.4 million | Underlying EBITA soared 38.3% to EUR81.5; the respective margin improves to 15.0% | Management raises full-year guidance for sales revenue In the first nine months of 2011, order intake for the Sartorius Group increased 8.5% (currency-adjusted: +10.0%) from EUR508.3 million to EUR551.3 million. Its sales revenue rose 12.2% (currency-adj.: +13.8%) to EUR541.4 million from EUR482.3 a year ago. The Biotechnology Division achieved an order intake of EUR365.7 million, up 10.5% (currency-adj.: +12.4%) from EUR330.9 million a year earlier, and boosted its sales revenue year on year by 10.9% (currency-adj.: +12.6%) to EUR353.5 million from EUR318.8 million. For the Mechatronics Division, order intake was up 4.6% (currency-adj.: +5.6%), to EUR185.7 million from EUR177.4 million); the division´s sales revenue grew 14.9% (currency-adj. +16.0%) to EUR187.9 million from EUR163.6 million in the previous year. Underlying EBITA surged from EUR58.9 million to EUR81.5 million; this reflects earnings before interest, taxes and amortization and is adjusted for extraordinary items of -EUR7.7 million (prev. yr.: -EUR3.3 million). The respective margin jumped from 12.2% to 15.0%. The Biotechnology Division contributed an underlying EBITA of EUR60.9 million, up from EUR50.1 million a year ago. Its margin increased accordingly from 15.7% to 17.2%. The Mechatronics Division more than doubled its contribution to earnings, from EUR8.8 million to EUR20.6 million; its earnings margin climbed from 5.4% to 10.9%. Excluding non-cash amortization, underlying net profit after non-controlling interest for the nine-month period totaled EUR38.0 million, up from EUR26.4 million a year earlier; the respective earnings per share were at EUR2.23, up from EUR1.55 a year ago. Based on the Group´s strong business performance, management has again revised its full-year 2011 guidance slightly upward: Sales in constant currencies are projected to grow for both divisions and thus also for the Group between 10% and 11% (former guidance: 8% to 10%). Earnings guidance is confirmed both for the two divisions and for the Group. Management therefore continues to expect that the Biotechnology Division and the Mechatronics Division will achieve an underlying EBITA margin of 17% to 18% and of 10% to 11% in constant currencies, respectively. At Group level, guidance remains unchanged for the operating EBITA margin, which is forecasted to improve to between 14.5% and 15.5%. Moreover, management continues to expect that operating cash flow will be significantly positive in 2011. Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of the Sartorius Group, will discuss the results with analysts and investors on Friday, October 21, 2011, at 3:30 p.m. Central European Time in a webcast teleconference. You may dial into the teleconference starting at 3:15 p.m. CET at the following numbers: Germany +49 (0)69 2999 3285; France +33(0)1 70 48 01 63; UK +44(0)20 7660 0009; USA +1 646 254 3375. The dial-in code is as follows: 3684539 The webcast and presentation can be viewed at www.sartorius.de. Goettingen, October 20, 2011 Further inquiry note: Andreas Theisen Phone +49(0) 551.308.1668 Fax +49(0)551.308.3153 andreas.theisen@ sartorius.com www.sartorius.com end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Sartorius AG Weender Landstr. 94-108 D-37075 Göttingen phone: +49 (0)551 308-0 FAX: +49 (0)551 308-3289 mail: info.investor@sartorius.com WWW: http://www.sartorius.com sector: Biotechnology ISIN: DE0007165607, DE0007165631 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English